Success Metrics

Clinical Success Rate

84.6%

Based on 11 completed trials

Completion Rate

85%(11/13)

Active Trials

0(0%)

Results Posted

100%(11 trials)

Terminated

2(15%)

Phase Distribution

Ph phase_1

23%

Ph phase_3

38%

Ph phase_4

Ph phase_2

31%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Phase 1Safety & dosage

3(23.1%)

Phase 2Efficacy & side effects

4(30.8%)

Phase 3Large-scale testing

5(38.5%)

Phase 4Post-market surveillance

1(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(11)

Terminated(2)

Detailed Status

Completed11

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

84.6%

Most Advanced

Phase 4

Trials by Phase

Phase 13 (23.1%)

Phase 24 (30.8%)

Phase 35 (38.5%)

Phase 41 (7.7%)

Trials by Status

terminated215%

completed1185%

Recent Activity

0 active trials

Showing 5 of 13

terminatedphase_1

Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)

NCT02013141

terminatedphase_3

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

NCT02208063

completedphase_2

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

NCT01321879

completedphase_3

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00091819

completedphase_2

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00061633

View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials

NCT02013141Phase 1

Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)

Terminated

NCT02208063Phase 3

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

Terminated

NCT01321879Phase 2

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

Completed

NCT00091819Phase 3

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

Completed

NCT00061633Phase 2

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

Completed

NCT00062647Phase 2

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

Completed

NCT00124020Phase 3

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

Completed

NCT00077675Phase 2

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

Completed

NCT00107978Phase 3

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

Completed

NCT00107952Phase 3

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

Completed

NCT01238796Phase 1

A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

Completed

NCT02392208Phase 4

Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5

Completed

NCT02753855Phase 1

Pharmacokinetics of Telavancin in Normal and Obese Subjects